Boston, United States
PostEra, founded in 2019, is a pioneering startup at the intersection of AI and biotechnology, headquartered in the United States. The company leverages its proprietary AI platform, Proton, to revolutionize medicinal chemistry, aiming to accelerate the discovery and development of new medicines.
Emphasizing Women's Health and Fertility, PostEra has successfully nominated multiple clinical candidates, notably PERA-5720 and PERA-8103. The company also partners with major pharmaceutical players like Pfizer and Amgen, securing over $1B in AI partnerships across multi-year agreements. Furthermore, it leads a pivotal antiviral drug discovery initiative for pandemic preparedness, buoyed by significant funding from the National Institute of Health, received as a grant investment on 01 May 2022.
With a slogan of "Medicinal Chemistry powered by Machine Learning," PostEra stands out as a potent force in integrating cutting-edge AI with biotech advancements, making it an attractive prospect for investors seeking innovation in healthcare.
